Group One Trading
CLDX icon

Group One Trading’s Celldex Therapeutics CLDX Stock Holding History

Group One Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-748
Closed -$20.4K – 7768
2025
Q4 		$20.3K Buy
+748
New +$19.7K ﹤0.01% 6327
2024
Q3 		– Sell
-8,757
Closed -$334K – 6716
2024
Q2 		$324K Sell
8,757
-599
-6% -$22.6K ﹤0.01% 2965
2024
Q1 		$393K Sell
9,356
-12,180
-57% -$500K ﹤0.01% 2966
2023
Q4 		$854K Buy
21,536
+3,780
+21% +$111K ﹤0.01% 2603
2023
Q3 		$489K Sell
17,756
-13,609
-43% -$427K ﹤0.01% 2930
2023
Q2 		$1.06M Buy
31,365
+11,241
+56% +$379K ﹤0.01% 2308
2023
Q1 		$724K Buy
20,124
+13,116
+187% +$566K ﹤0.01% 2413
2022
Q4 		$312K Sell
7,008
-6,781
-49% -$242K ﹤0.01% 3462
2022
Q3 		$388K Sell
13,789
-14,531
-51% -$445K ﹤0.01% 3484
2022
Q2 		$764K Buy
28,320
+8,544
+43% +$248K ﹤0.01% 3003
2022
Q1 		$674K Sell
19,776
-25,432
-56% -$813K ﹤0.01% 3495
2021
Q4 		$1.75M Buy
45,208
+17,957
+66% +$783K ﹤0.01% 2753
2021
Q3 		$1.47M Buy
27,251
+968
+4% +$45.4K ﹤0.01% 2984
2021
Q2 		$879K Sell
26,283
-56,354
-68% -$1.55M ﹤0.01% 3568
2021
Q1 		$1.7M Buy
82,637
+58,478
+242% +$1.34M ﹤0.01% 2644
2020
Q4 		$423K Buy
+24,159
New +$435K ﹤0.01% 3416
2020
Q2 		– Sell
-10,065
Closed -$44.6K – 5816
2020
Q1 		$17K Sell
10,065
-805
-7% -$1.82K ﹤0.01% 4309
2019
Q4 		$24K Sell
10,870
-6,967
-39% -$16.2K ﹤0.01% 4296
2019
Q3 		$38K Buy
17,837
+10,900
+157% +$25.2K ﹤0.01% 4106
2019
Q2 		$19K Sell
6,937
-4,011
-37% -$13.6K ﹤0.01% 4192
2019
Q1 		$54K Buy
10,948
+10,216
+1,396% +$53.7K ﹤0.01% 3526
2018
Q4 		$2K Sell
732
-1,282
-64% -$6.3K ﹤0.01% 4648
2018
Q3 		$14K Sell
2,014
-3,488
-63% -$24.4K ﹤0.01% 4524
2018
Q2 		$42K Buy
5,502
+1,561
+40% +$20.9K ﹤0.01% 4042
2018
Q1 		$138K Sell
3,941
-662
-14% -$25.7K ﹤0.01% 3034
2017
Q4 		$196K Buy
4,603
+1,087
+31% +$46.6K ﹤0.01% 2937
2017
Q3 		$151K Buy
3,516
+614
+21% +$23K ﹤0.01% 2959
2017
Q2 		$108K Sell
2,902
-2,754
-49% -$122K ﹤0.01% 3056
2017
Q1 		$306K Sell
5,656
-3,597
-39% -$187K ﹤0.01% 2218
2016
Q4 		$491K Buy
9,253
+164
+2% +$9.33K ﹤0.01% 1786
2016
Q3 		$551K Sell
9,089
-1,926
-17% -$120K 0.01% 1743
2016
Q2 		$725K Buy
11,015
+4,238
+63% +$269K 0.01% 1453
2016
Q1 		$384K Sell
6,777
-23,574
-78% -$2.65M 0.01% 1867
2015
Q4 		$7.14M Sell
30,351
-11,468
-27% -$2.5M 0.08% 248
2015
Q3 		$6.61M Buy
41,819
+23,660
+130% +$6.7M 0.09% 255
2015
Q2 		$6.87M Sell
18,159
-4,015
-18% -$1.59M 0.1% 228
2015
Q1 		$9.27M Buy
22,174
+9,749
+78% +$3.49M 0.15% 117
2014
Q4 		$3.4M Buy
12,425
+2,890
+30% +$718K 0.05% 414
2014
Q3 		$1.85M Sell
9,535
-4,750
-33% -$1.03M 0.03% 729
2014
Q2 		$3.5M Sell
14,285
-366
-2% -$82.6K 0.05% 418
2014
Q1 		$3.88M Buy
14,651
+179
+1% +$68.5K 0.07% 316
2013
Q4 		$5.26M Buy
14,472
+6,702
+86% +$2.58M 0.08% 241
2013
Q3 		$4.13M Buy
7,770
+2,787
+56% +$956K 0.08% 264
2013
Q2 		$1.17M Buy
+4,983
New +$981K 0.03% 710

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading's CLDX Position: Q1 2026 in Review

Group One Trading sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 748 shares — an estimated $20.4K sold.

Group One Trading first reported a position in CLDX in Q2 2013 and held it in 44 quarters. The position peaked at $9.27M in Q1 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Group One Trading reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 748 Celldex Therapeutics shares in Q1 2026, an estimated $20.4K.
  • Group One Trading first reported a position in Celldex Therapeutics in Q2 2013 and held it in 44 quarters.
  • Group One Trading's Celldex Therapeutics position peaked at $9.27M in Q1 2015.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.